Patents by Inventor Alan B. Cooper

Alan B. Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds that are ERK inhibitors
    Patent number: 8546404
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: October 1, 2013
    Assignee: Merck Sharp & Dohme
    Inventors: Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, Jr., Neng-Yang Shih, Hugh Y. Zhu, Robert Sun, Joseph M. Kelly, Ronald J. Doll, Yang Nan, Tong Wang, Jagdish A. Desai, James J-S Wang, Youhao Dong, Vincent S. Madison, Li Xiao, Alan W. Hruza, M. Arshad Siddiqui, Ahmed A. Samatar, Sunil Paliwal, Hon-Chung Tsui, Azim Alan Celebi, Yiji Wu, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Mehul Patel
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20130237518
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Application
    Filed: October 24, 2011
    Publication date: September 12, 2013
    Inventors: Sobhana Babu Boga, Joseph M. Kelly, Hugh Y. Zhu, Abdul-Basit Alhassan, Xin Yao, Xiaolei Gao, James J-S Wang, Jagdish A. Desai, Subrahmanyam Gudipati, Sie-Mun Lo, Liang Zhu, Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, JR.
  • FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS
    Publication number: 20130172341
    Abstract: Disclosed are the ERK inhibitors of Formula (I): (Formula (I)) and the pharmaceutically acceptable salts thereof. All substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (I).
    Type: Application
    Filed: September 12, 2011
    Publication date: July 4, 2013
    Inventors: Gerald W. Shipps, JR., Yongqi Deng, Alan B. Cooper, Xiaolei Gao, Binyuan Sun, James Wang, Liang Zhu
  • INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS
    Publication number: 20130158020
    Abstract: The present invention provides a compound of the Formula I: Formula I or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2, R3, R4, X, m and n are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.
    Type: Application
    Filed: August 29, 2011
    Publication date: June 20, 2013
    Inventors: Yongqi Deng, Gerald W. Shipps, JR., Sie-Mun Lo, Liang Zhu, Alan B. Cooper, Kiran Muppalla
  • NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS
    Publication number: 20130096084
    Abstract: The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.
    Type: Application
    Filed: June 22, 2011
    Publication date: April 18, 2013
    Inventors: Yongqi Deng, Liang Zhu, Gerald W. Shipps, JR., Sie-Mun Lo, Binyuan Sun, Xiaohua Huang, Corey Bienstock, Alan B. Cooper, Xiaolei Gao, Xin Yao, Hugh Y. Zhu, Joseph M. Kelly, Sobhana Babu Boga, Abdul-Basit Alhassan, Jayaram R. Tagat, Umar Faruk Mansoor, Kevin J. Wilson, Brendan M. O'Boyle, Matthew Hersh Daniels, Adam Schell, Phieng Siliphaivanh, Christian Fischer
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20120214823
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: (Formula (A1)), and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine ring that can have a bridge or a fused ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula A1.
    Type: Application
    Filed: September 20, 2010
    Publication date: August 23, 2012
    Inventors: Hugh Y. Zhu, Jagdish A. Desai, Alan B. Cooper, Ronald J. Doll
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20110189192
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Application
    Filed: February 19, 2009
    Publication date: August 4, 2011
    Inventors: Alan B. Cooper, Yang Nan, Yongqi Deng, Gerald W. Shipps, JR., Neng-Yang Shih, Hugh Y. Zhu, Joseph M. Kelly, Subrahmanyam Gudipati, Ronald J. Doll, Mehul F. Patel, Jagdish A. Desai, James J-S Wang, Sunil Paliwal, Hon-Chung Tsui, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Xin Yao
  • HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS
    Publication number: 20110038876
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Application
    Filed: June 17, 2008
    Publication date: February 17, 2011
    Inventors: Robert Sun, Alan B. Cooper, Yongqi Deng, Tong Wang, Yang Nan, Hugh Y. Zhu, Sobhana Babu Boga, Xiaolei Gao, Joseph M. Kelly, Sunil Paliwal, Hon-Chung Tsui, Ronald J. Doll, Neng-Yang Shih
  • Farnesyl protein transferase inhibitors as antitumor agents
    Patent number: 7557107
    Abstract: Disclosed are novel tricyclic compounds of the formula: and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: July 7, 2009
    Assignee: Schering Coporation
    Inventors: Hugh Y. Zhu, Alan B. Cooper, Jagdish A. Desai, James J-S Wang, Ronald J. Doll, F. George Njoroge, Viyyoor M. Girijavallabhan
  • Novel compounds that are ERK inhibitors
    Publication number: 20090118284
    Abstract: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Application
    Filed: June 5, 2007
    Publication date: May 7, 2009
    Inventors: Alan B. Cooper, Yongqi Deng, Gerald W. Shipps, JR., Neng-Yang Shih, Hugh Y. Zhu, Robert Sun, Joseph M. Kelly, Ronald J. Doll, Yang Nan, Tong Wang, Jagdish A. Desai, James J-S Wang, Youhao Dong, Vincent S. Madison, Li Xiao, Alan W. Hruza, M. Arshad Siddiqui, Ahmed A. Samatar, Sunil Paliwal, Hon-Chung Tsui, Azim Alan Celebi, Yiji Wu, Sobhana Babu Boga, Abdul-Basit Alhassan, Xiaolei Gao, Liang Zhu, Mehul Patel
  • Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
    Patent number: 7425640
    Abstract: The present invention provides compounds of formula I wherein X, Y, R1-R7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: September 16, 2008
    Assignee: Schering Corporation
    Inventors: Alan B. Cooper, Hugh Y. Zhu, James J-S Wang, Jagdish A. Desai, Gerald W. Shipps, Jr., Patrick J. Curran, D. Allen Annis, Huw M. Nash, Viyyoor M. Girijavallabhan
  • Farnesyl protein transferase inhibitors as antitumor agents
    Patent number: 7342016
    Abstract: Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: March 11, 2008
    Assignees: Schering Corporation, Pharmacopeia, Inc.
    Inventors: Hugh Y. Zhu, F. George Njoroge, Alan B. Cooper, Timothy J. Guzi, Dinanath F. Rane, Keith P. Minor, Ronald J. Doll, Viyyoor M. Girijavallabhan, Bama Santhanam, Patrick A. Pinto, Bancha Vibulbhan, Kartik M. Keertikar, Carmen S. Alvarez, John J. Baldwin, Ge Li, Chia-Yu Huang, Ray A. James, James J-S Wang, Jagdish A. Desai
  • Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
    Patent number: 7115749
    Abstract: The present invention provides compounds of formula I wherein X and R1–R7 are as defined herein.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: October 3, 2006
    Assignee: Schering Corporation
    Inventors: Gerald W. Shipps, Jr., Tong Wang, Kristin E. Rosner, Patrick J. Curran, Alan B. Cooper, Viyyoor M. Girijavallabhan
  • Farnesyl protein transferase inhibitors
    Patent number: 6800636
    Abstract: Disclosed are compounds of the formula: wherein R8 represents a cyclic moiety to which is bound an imodazolylalkyl group; R9 represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: October 5, 2004
    Assignee: Schering Corporation
    Inventors: Timothy Guzi, Dinanath F. Rane, Alan K. Mallams, Alan B. Cooper, Ronald J. Doll, Viyyoor M. Girijavallabhan, Arthur G. Taveras, Corey Strickland, Joseph M. Kelly, Jianping Chao
  • Compounds useful for inhibition of farnesyl protein transferase
    Publication number: 20040157872
    Abstract: Novel compounds of the formula: 1
    Type: Application
    Filed: February 9, 2004
    Publication date: August 12, 2004
    Inventors: Alan B. Cooper, Ronald J. Doll, Anil K. Saksena, Viyyoor M. Girijavallabhan
  • Novel farnesyl protein transferase inhibitors as antitumor agents
    Publication number: 20040122018
    Abstract: Disclosed are novel tricyclic compounds represented by the formula (1.
    Type: Application
    Filed: December 19, 2002
    Publication date: June 24, 2004
    Applicant: Schering Corporation
    Inventors: Hugh Y. Zhu, F. George Njoroge, Alan B. Cooper, Timothy Guzi, Dinanath F. Rane, Keith P. Minor, Ronald J. Doll, Viyyoor M. Girijavallabhan, Bama Santhanam, Patrick A. Pinto, Bancha Vibulbhan, Kartik M. Keertikar, Carmen S. Alvarez, John J. Baldwin, Ge Li, Chia-Yu Huang, Ray A. James, W. Robert Bishop, James J-S Wang, Jagdish A. Desai
  • Farnesyl protein transferase inhibitors
    Patent number: 6740661
    Abstract: Disclosed are compounds of the formula: wherein R13 represents an imidazole ring; R14 represents a carbamate, urea, amide or sulfonamide group; R8 represents H when the alkyl chain between the amide group and the R13 imidazole group is substituted, or R8 represents a substituent such as arylalkyl, heteroarylalkyl or cycloalkyl; and the remaining substituents are as defined herein. Also disclosed are compounds wherein R8 is H, and the alkyl chain between the amide group and the R13 imidazole group is unsubstituted. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: May 25, 2004
    Assignee: Schering Corporation
    Inventors: Arthur G. Taveras, Ronald J. Doll, Alan B. Cooper, Johan A. Ferreira, Timothy Guzi, Alan K. Mallams, Dinanath F. Rane, Viyyoor M. Girijavallabhan, Adriano Afonso, Cynthia J. Aki, Jianping Chao, Carmen Alvarez, Joseph M. Kelly, Tarik Lalwani, Jagdish A. Desai, James J-S Wang, Jay Weinstein
  • Treatment of malaria with farnesyl protein transferase inhibitors
    Publication number: 20040087592
    Abstract: Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance.
    Type: Application
    Filed: October 21, 2003
    Publication date: May 6, 2004
    Inventors: William T. Windsor, Patricia C. Weber, James J-S. Wang, Corey O. Strickland, F. George Njoroge, Timothy J. Guzi, Viyyoor M. Girijavallabhan, Johan A. Ferreira, Jagdish A. Desai, Alan B. Cooper, Michael Gelb
  • Compounds useful for inhibition of farnesyl protein transferase
    Patent number: 6689789
    Abstract: Novel compounds of the formula: or a pharmaceutically acceptable salt or solvate thereof, wherein: a represents N or NO−; R1 and R3 are the same or different and each represents halo; R2 and R4 are the same or different and each is selected from H and halo, provided that at least one of R2 and R4 is H; T is a substituent selected from SO2R or Z is O or S; n is zero or an integer from 1 to 6; R is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or N(R5)2; R5 is H, alkyl, aryl, heteroaryl or cycloalkyl. Also disclosed are methods of inhibiting farnesyl protein transferase and methods for treating tumor cells.
    Type: Grant
    Filed: September 4, 2002
    Date of Patent: February 10, 2004
    Assignee: Schering Corporation
    Inventors: Alan B. Cooper, Ronald J. Doll, Anil K. Saksena, Viyyoor M. Girijavallabhan
  • Novel farnesyl protein transferase inhibitors as antitumor agents
    Publication number: 20030229099
    Abstract: Disclosed are novel tricyclic compounds represented by the formula (1.
    Type: Application
    Filed: February 27, 2002
    Publication date: December 11, 2003
    Inventors: Hugh Y. Zhu, F. George Njoroge, Alan B. Cooper, Timothy Guzi, Dinanath F. Rane, Keith P. Minor, Ronald J. Doll, Viyyoor M. Girijavallabhan, Bama Santhanam, Patrick A. Pinto, Bancha Vibulbhan, Kartik M. Keertikar, Carmen S. Alvarez, John J. Baldwin, Ge Li, Chia-Yu Huang, Ray A. James, W. Robert Bishop, James J-S Wang, Jagdish A. Desai